TSX closed
Loading markets…

Advertisement

PARTNER SPOTLIGHT

CIBC Investor's Edge

Invest your way with confidence.

  • ✓Powerful tools & research — at no extra cost
  • ✓Stocks, ETFs, options & more
  • ✓Competitive fees + USD accounts
Stocks/NASDAQ/MRNA

Moderna Inc (MRNA : NASDAQ)

Common Stock

$197.00

USD

+0.52 (0.26%)

Last updated: 2026-10-08

Follow MRNA

MRNA

Moderna Inc

Source:WealthAwesomeWealthAwesome
↑ $54.23 (37.98%)
30 day period
$135.61$169.54$203.46Aug 27Sep 18Oct 8

Performance

1 Day

+0.26%

1 Week

+4.27%

1 Month

+40.38%

YTD

+538.37%

Key Statistics

Market Cap

$78.65B

52W High

$212.22

52W Low

$22.28

P/E Ratio

-

50 Day MA

$132.07

200 Day MA

$70.86

Beta

1.09

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

↑Above 50 SMA

Price vs 200-Day SMA

↑Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
10/8/2026$196.42$199.92$192.71$197.00$197.0037,399,978
10/7/2026$183.65$197.69$182.50$196.48$196.4814,640,181
10/6/2026$202.09$212.22$186.64$187.46$187.4618,794,807
10/5/2026$191.41$205.77$185.90$203.21$203.2119,313,307
10/2/2026$190.26$193.72$183.28$190.01$190.0110,274,100
10/1/2026$186.61$201.00$186.01$188.94$188.9415,437,000
9/30/2026$186.55$196.83$184.58$192.57$192.5720,649,500
9/29/2026$197.78$208.90$190.00$203.46$203.4613,277,900
9/28/2026$195.16$199.82$189.10$197.28$197.2813,359,600
9/25/2026$195.34$202.67$192.51$198.88$198.8813,945,000

Analyst Price Targets

Based on 23 analysts covering MRNA · as of Oct 8, 2026

📉

Wall Street analysts forecast MRNA stock price to fall 38.6% over the next 12 months.

Consensus

Hold

3.17 / 5.00

Avg. Target

US$121.00

-38.6% Upside

Previously US$120.67 on Oct 5, 2026

Current Price

US$197.00

Last close

Analyst Breakdown (23 analysts)

Strong Buy 4
Buy 1
Hold 15
Sell 1
Strong Sell 2
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on MRNA's historical volatility

HistoricalForecast68%95%
US$44.27US$153.63US$262.99US$372.35US$481.71US$591.07TodayJun 2Aug 6Oct 8Nov 20Jan 3Feb 15

30-Day Vol

74.5%

Annualized

90-Day Vol

194.0%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

US$235.52

Expected price

HorizonExpected68% Range (1σ)
30 trading daysUS$209.08US$161.68 – US$270.38
60 trading daysUS$221.91US$154.26 – US$319.21
90 trading daysUS$235.52US$150.88 – US$367.63

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Moderna Inc

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Financials

Revenue (TTM)
$2.23B
EBITDA
$-2.20B
Profit Margin
-141.43%
ROE (TTM)
-39.00%
EPS (Diluted)
-7.98
Book Value
16.95

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About MRNA.US

Market movers

Recent NASDAQ movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
FLYEFly-E Group, Inc. Common Stock$2.32+82.68%
JZJianzhi Education Technology Group Company Limited American Depositary Shares$0.83+77.52%
EURKREureka Acquisition Corp Right$0.44+62.87%
AIXIXIAO-I Corporation$1.93+46.21%
PCRXPacira BioSciences, Inc.$36.39+44.40%
QNMEQuanome Technologies, Inc.$0.83+43.28%
OLBOLB Group Inc$0.55+41.86%
RITRFReitar Logtech Holdings Limited$0.01+33.33%

MRNA.US news timeline

15 articles covering MRNA.US, most recent first

Latest

Why Moderna stock is skyrocketing today

•Stocks

Advertisement